1、Rb2、Rb3、Rc、Rd、Rg1、Rg2、Rg3、Rh1、Ro、F2,五味子甲素,五味子乙素,五味子醇甲,五味子醇乙進行VEGF受體結合強度的檢測分析;CCK-8法檢測篩選出的成分(5、10 μg/mL)對ECV304細胞的促增殖作用。結果 Western blotting結果顯示,ECV304細胞中VEGF受體高表達;人參皂苷Rb1、Rb2、Rb3、Rc、Rd、Rg3、Rh1、F2、五味子甲素、五味子乙素與VEGF受體CMC柱有結合作用;CCK-8法檢測以上成分對ECV304細胞的活力影響發(fā)現(xiàn),人參皂苷Rb2能促進細胞的增殖。結論 人參皂苷Rb2能與VEGF受體結合,且顯著促進ECV304細胞增殖。;Objective To detect and analyze the effect of 15 components from ginseng saponins and schisandra lignin on angiogenesis by cell membrane chromatography. Methods Western blotting detection was used to screen the cell lines with high expression of VEGF receptor. Cell membrane chromatographic column was prepared by ECV304 cell membrane and ECV304/CMC online-LC detection method was established. With sorafenib as a positive drug, the receptor binding strength of VEGF was detected and analyzed for ginsenosides Rb1,Rb2,Rb3,Rc,Rd,Rg1,Rg2,Rg3,Rh1,Ro,F2, deoxyschizandrin, γ -schizandrin, schisandrol A, schisandrol B. CCK-8 assay was used to detect the proliferative effects of the selected ingredients (5 and 10 μg/mL) on ECV304 cells. Results Western blotting results showed that VEGF receptor was highly expressed in ECV304 cells. It was found that ginsenoside Rb1,Rb2,Rb3,Rc,Rd,Rg3,Rh1,F2, schisandrin A and schisandrin B had binding effect. CCK-8 assay showed that ginsenoside Rb2 could promote the proliferation of ECV304 cells. Conclusion Ginsenoside Rb2 can bind to angiogenic VEGF receptor, and can significantly promote the proliferation of ECV304."/> 2;血管新生;活性成分;人參皂苷;五味子甲素;五味子乙素;五味子醇甲;五味子醇乙;cell membrane chromatography;ginsenoside Rb2;angiogenesis;active ingredients;ginsenosides;deoxyschizandrin;γ-schizandrin;schisandrol A;schisandrol B"/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2021年第44卷第11期 >2021,44(11):2379-2384. DOI:10.7501/j.issn.1674-6376.2021.11.012
上一篇 | 下一篇

基于細胞膜色譜技術的人參皂苷及五味子木脂素與血管內(nèi)皮生長因子受體的作用分析

Detection of effects of ginseng saponins and schisandra lignin on vascular endothelial growth factor receptor by cell membrane chromatography

發(fā)布日期:2021-11-10
您是第位訪問者
藥物評價研究 ® 2025 版權所有
技術支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務資格證書編號:(津)-非經(jīng)營性-2015-0031